Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Total Debt
Short-term and long-term borrowings combined.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Total Debt · Q3 FY2026 · quarter ended Sep 2026
Total debt rises 253.1% from a year ago
Total debt stood at $6.48B at the end of Q3 FY2026, up 253.1% from a year earlier and up 227.6% from the prior quarter. Over 3 fiscal years it compounded at +62.8% a year.
Context
- Total debt amounted to 19.8% of total assets at the end of Q3 FY2026, up 12.4 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +253.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 3.88B USD
- Year-over-year change
- +121.9%
- 4-year CAGR
- +41.5%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.88B | +121.9% |
| FY2024 | 2024-12-31 | 1.75B | +116.4% |
| FY2023 | 2023-12-31 | 808.4M | -10.1% |
| FY2022 | 2022-12-31 | 899.7M | -7.0% |
| FY2021 | 2021-12-31 | 967.4M | — |
Total Debt vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's Sep 2026 total debt of $6.48B is the 2nd highest of the 11 companies compared; the peer median is $1.12B.
- Its year-over-year change of +253.1% is the 3rd highest of 11, against a peer median of +52.2%.
- Total debt amounts to 19.8% of total assets for VRTX, versus a peer median of 26.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $658.72B | +108915.6% | -16.2% | 5.7% | |
| Sep 2026 | $6.48B | +253.1% | +62.8% | 19.8% | |
| Jun 2026 | $2.49B | -6.8% | +16.5% | 204.9% | |
| Sep 2026 | $2.15B | +44.5% | +24.1% | 73.9% | |
| Jun 2026 | $1.27B | -2.3% | -1.1% | 22.8% | |
| Mar 2026 | $1.2B | +3035.4% | +243.1% | 92.6% | |
| Mar 2026 | $1.04B | -22.9% | -13.7% | 32.6% | |
| Sep 2026 | $779.83M | +93.1% | +17.4% | 30.5% | |
| Jun 2026 | $696.47M | +79.4% | +22.8% | 21.4% | |
| Jun 2026 | $247.36M | +59.8% | +18.0% | 17.8% | |
| Mar 2026 | $80.49M | -32.5% | -10.6% | 10.6% | |
| Peer median (excluding VRTX) | $1.12B | +52.2% | +17.0% | 26.7% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.8B | 10.5B | 10.37B | 4.57B | 5.09B |
| Short-term Investments | 729.9M | 274.5M | 849.2M | 1.55B | 1.52B |
| Net Receivables | 1.14B | 1.44B | 1.56B | 1.61B | 2.05B |
| Inventory | 353.1M | 460.6M | 738.8M | 1.21B | 1.69B |
| Other Current Assets | 103.7M | 121.9M | 86.1M | 206.5M | 748.6M |
| Total Current Assets | 9.56B | 13.23B | 14.14B | 9.6B | 11.2B |
| Property, Plant & Equipment (Net) | 1.42B | 1.46B | 1.45B | 2.58B | 3.08B |
| Goodwill | 1B | 1.09B | 1.09B | 1.09B | 1.09B |
| Intangible Assets | 400M | 603.6M | 839.9M | 825.9M | 424.2M |
| Long-term Investments | 0 | 112.2M | 2.5B | 5.11B | 5.81B |
| Tax Assets | 934.5M | 1.25B | 1.81B | 2.33B | 3.4B |
| Other Non-current Assets | 110.8M | 409.6M | 895.3M | 999.3M | 1.14B |
| Total Non-current Assets | 3.87B | 4.92B | 8.59B | 12.94B | 14.94B |
| Total Assets | 13.43B | 18.15B | 22.73B | 22.53B | 26.14B |
| Account Payables | 195M | 303.9M | 364.9M | 413M | 461.7M |
| Short-term Debt | 0 | 0 | 0 | 92.3M | 82.8M |
| Tax Payables | 211.3M | 123.3M | 99.5M | 161.1M | 0 |
| Deferred Revenue | 171.7M | 159.6M | 170.3M | 206.8M | 171.8M |
| Other Current Liabilities | 16.5M | 62.5M | 50.7M | 2.5B | 2.75B |
| Total Current Liabilities | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.85B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.31B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 303.3M | 685.8M | 877.7M | 901.8M | (1.49B) |
| Total Non-current Liabilities | 1.19B | 1.5B | 1.6B | 2.56B | 3.62B |
| Total Liabilities | 3.33B | 4.24B | 5.15B | 6.12B | 7.48B |
| Common Stock | 2.5M | 2.6M | 2.6M | 2.6M | 2.5M |
| Retained Earnings | 3.2B | 6.52B | 10.14B | 9.61B | 13.56B |
| Accumulated OCI | 15.9M | 800K | (14.3M) | 127.8M | (15.9M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.1B | 13.91B | 17.58B | 16.41B | 18.67B |
| Total Debt | 967.4M | 899.7M | 808.4M | 1.75B | 3.88B |
| Net Debt | (5.83B) | (9.6B) | (9.56B) | (2.82B) | (1.21B) |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.